Pembrolizumab is noninferior to standard chemotherapy for overall survival (OS) in advanced gastric or gastroesophageal junction (G/GEJ) cancer in the first-line setting, thus providing a potential alternative treatment option for patients with G/GEJ, according to the KEYNOTE-062 study presented at ASCO 2019.
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.
The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress™ (ILC 2019).
Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress™ (ILC 2019).
Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress™ (ILC 2019).
The incidence of Clostridium difficile (C. difficile) infection among patients with ulcerative colitis (UC) who are receiving treatment with tofacitinib is low and particularly so when compared with C. difficile infection incidence in patients receiving other UC therapies, according to a poster presented at AIBD 2018.